Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses the CREATE-X adjuvant study of capecitabine in high-risk patients with residual disease (Abstract S6-01).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Joseph A. Sparano, MD, of Montefiore Medical Center, discuss this study of high-risk premenopausal luminal A breast cancer patients receiving adjuvant chemotherapy (Abstract S1-08).
Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).
Sherene Loi, MD, of Peter MacCallum Cancer Centre, discusses a pooled individual patient data analysis of stromal tumor-infiltrating lymphocytes in primary triple-negative breast cancer treated with anthracycline-based chemotherapy (Abstract S1-03).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and William J. Gradishar, MD, of the Lurie Comprehensive Cancer Center, discuss the most important papers and results at this year's San Antonio Breast Cancer Symposium.
Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well as the preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor–positive/HER2-negative disease (Abstracts S1-04, S5-07).
